View Press Releases

Rho Experts Share Approach for Maximizing Benefits of Decentralized Trials During Free Webinar

August 19, 2020
CRO shares best practices and solutions to help sponsors get the most out of their hybrid, virtual and synthetic clinical trials

DURHAM, NC, US - Aug 20, 2020 - MEDIA ADVISORY

Rho Experts Share Approach for Maximizing Benefits of Decentralized Trials During Free Webinar

CRO shares best practices and solutions to help sponsors get the most out of their hybrid, virtual and synthetic clinical trials

 

WHAT:                 Rho, a full-service contract research organization (CRO) with a proven track record of drug development success, will discuss its approach to and solutions for maximizing the benefits of decentralized clinical trials in an upcoming webinar, “CROs: The Tip of the Spear in Maximizing the Value of Hybrid, Virtual, and Synthetic Clinical Trials.” The webinar will take place on Wednesday, August 26, from 1-2 p.m. EST.

 

Rho’s Chief Strategist of Biostatistics and Standards for Regulatory Submissions Rob Woolson and Associate Director of Data Management Derek Lawrence will present the webinar, which will provide insights into Rho’s approach to maximizing the benefits of decentralized trials, especially as hybrid, virtual and synthetic clinical trials are becoming a part of an increasing number of drug and biologics development programs. The webinar will discuss various solutions that can benefit sponsors, including: bridging the gap across an ever-increasing number of data collection systems; leveraging the information real-time; and bringing this information to bear on business decisions, clinical trial execution decisions and marketing application dossiers.

 

WHO:                    Rob Woolson, chief strategist of biostatistics and standards for regulatory submissions at Rho, has 14 years of experience in the analysis of complex data. He has conducted statistical analyses in all phases of drug development (Phase I through IV, NDAs and BLAs) and has led SDTM/ADaM dataset conversion projects in multiple therapeutic areas. He has held a leadership role in six CDISC-compliant regulatory submissions, having guided the creation of ISS/ISE statistical analysis plans; integrated analysis dataset design and production; integrated display design and production; and submission-related documentation development. He has authored responses to numerous FDA queries and has represented sponsors at FDA in-person meetings.

 

Derek Lawrence, associate director of data management at Rho, has over 10 years of data management and analysis experience in the health care/pharmaceutical industry, working to advance programmatic automation, integration, and streamlining of work between functional areas across numerous therapeutic areas. He serves as one of Rho's Biometrics Leads, an internal expert responsible for disseminating the application of new technology, best practices, and processes and is responsible for overseeing the development, integration, and maintenance of clinical data capture systems, executing metadata-driven programmatic solutions to database development & data cleaning, creating and implementing analytics solutions, and fostering inter-functional area collaboration and innovation.

 

WHEN:                 August 26, 2020
                                1-2 p.m. EST

 

WHERE:               Register to attend this free webinar at this link.

 

DETAILS:              For media inquiries, please contact Melody Goforth at Largemouth Communications, 919-459-6482, melody@largemouthpr.com.   

 

ABOUT:                Rho, a privately held contract research organization (CRO) located in NC’s Research Triangle Park, provides a full range of drug development services from program strategy through clinical trials and marketing applications. For more than 35 years, Rho has been a trusted partner to some of the industry’s most innovative pharmaceutical, biotechnology and medical device companies, as well as academic and government organizations. Rho’s cross-functional collaborative approach, therapeutic expertise, and commitment to strong site relationships changes what it means to work with a CRO - ultimately accelerating time to market, maximizing returns on investment, and ensuring a consistent program that runs smarter and more efficiently. Experience Rho by following us on Facebook, LinkedIn and Twitter.

 

###